

PROLIGHT DIAGNOSTICS PUBLISHES INVESTOR LETTER FOR JULY 2023

Prolight Diagnostics publishes an investor letter for July 2023. In the investor letter, you can read about the launch of the company's new website and that Prolight Diagnostics is now present at the 2023 AACC Annual Scientific Meeting + Clinical Lab Expo in the USA.

Link to investor letters:

<https://prolightdx.com/en/mediaeng/investor-letters/>

For further information, please contact:

Prolight Diagnostics AB (publ)

E-mail: ub@prolightdx.com

Telephone: +46 73 582 39 87

Website: www.prolightdx.com/en/

About Us

Prolight Diagnostics, together with the subsidiary Psyros Diagnostics and technology partners, develops innovative and flexible near-patient testing, Point-of-Care (POC) systems, based on patented technology. POC tests are performed outside the traditional hospital laboratory with small mobile instruments in ambulances, health centres, nursing homes, emergency departments, intensive care units, and other settings, enabling testing close to the patient and with rapid test results. With this technology, health care providers will be able to sort out patients in need of rapid treatment from patients that, for example, are not having a heart attack. The sales value of the global POC testing market amounted to USD 34.6 billion in 2021 and is growing strongly. (1.)

The company's share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.

(1. Global Market Insights, Point of Care Testing Market 2022-2030, juli 2022)

Attachments

[Investerarbrev 25 Juli 2023 Eng](#)

[Prolight Diagnostics publishes investor letter for July 2023](#)